Thymol

Identification

Name
Thymol
Accession Number
DB02513  (EXPT01913)
Type
Small Molecule
Groups
Approved
Description

A phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)

Structure
Thumb
Synonyms
  • 2-isopropyl-5-methylphenol
  • 5-Methyl-2-(1-Methylethyl)Phenol
  • IPMP
External IDs
FEMA NO. 3066 / NSC-11215 / NSC-47821 / NSC-49142
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acne Vanish Synergy for treatment of AcnesOil.7 g/50gTopicalPhytopia Co., Ltd.2016-02-29Not applicableUs
Acute Bronchitis SynergyOil1.5 g/50gTopicalPhytopia Co., Ltd.2016-02-29Not applicableUs
Benefect Natural Hand SanitizerSpray.06 mL/120mLTopicalSensible Life Products2010-03-01Not applicableUs
Benefect Natural Hand SanitizerLiquid.5 mL/LTopicalSensible Life Products2010-03-01Not applicableUs
Chronic Bronchitis SynergyOil.5 g/50gTopicalPhytopia Co., Ltd.2016-02-29Not applicableUs
Cleanwell Natural Antibacterial Foaming LavenderSoap.0004 kg/kgTopicalClean Well, Llc2007-11-012019-05-29Us
CleanWell Natural Antibacterial Foaming Orange VanillaSoap.0004 1/kgTopicalClean Well, Llc2007-11-012019-05-29Us
CleanWell Natural Antibacterial Foaming Spearmint LimeSoap.0004 kg/kgTopicalClean Well2007-11-01Not applicableUs
CleanWell Natural Orange Vanilla Hand SanitizerSpray.0005 kg/kgTopicalClean Well2007-11-01Not applicableUs
CleanWell Natural Orange Vanilla Hand Sanitizing WipesCloth.0005 kg/kgTopicalClean Well2010-06-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advanced AntisepticThymol (.064 mL/100L) + Eucalyptol (.042 mL/100L) + Menthol (.042 mL/100L) + Methyl salicylate (.06 mL/100L)MouthwashOralWakfern Food Corporation2010-11-24Not applicableUs
Advanced AntisepticThymol (.064 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Methyl salicylate (.06 kg/100L)MouthwashOralDemoulas Supermarkets, Inc.2010-07-22Not applicableUs
Advanced Antiseptic CitrusThymol (.042 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Methyl salicylate (.06 mL/100L)MouthwashOralDrug Mart1991-06-15Not applicableUs
Advanced Antiseptic CitrusThymol (.042 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Methyl salicylate (.06 mL/100L)MouthwashOralH.E.B.2010-10-15Not applicableUs
Advanced CitrusThymol (.064 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Methyl salicylate (.06 kg/100L)MouthwashOralWalmart Stores2010-07-22Not applicableUs
Advanced Citrus AntisepticThymol (.064 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Methyl salicylate (.06 mL/100L)MouthwashOralPublix Supermarkets, Inc.2001-05-03Not applicableUs
Amber Mouth RinseThymol (.64 mg/mL) + Eucalyptol (.92 mg/mL) + Menthol (.42 mg/mL) + Methyl salicylate (.6 mg/mL)LiquidOralFilo America2013-07-30Not applicableUs
Amber Mouth Wash - LiqThymol (0.064 %) + Eucalyptol (0.092 %) + Menthol (0.042 %)LiquidDentalPerrigo International1996-10-091999-08-06Canada
Amber Mouthwash - LiqThymol (0.064 %) + Eucalyptol (0.092 %) + Menthol (0.042 %)LiquidDentalPerrigo International1996-06-301999-08-06Canada
Anitseptic Mouth RinseThymol (.64 mg/mL) + Eucalyptol (.92 mg/mL) + Menthol (.42 mg/mL) + Methyl salicylate (.6 mg/mL)MouthwashOralPharmacy Vlaue Alliance Llc2003-08-19Not applicableUs
Categories
UNII
3J50XA376E
CAS number
89-83-8
Weight
Average: 150.2176
Monoisotopic: 150.10446507
Chemical Formula
C10H14O
InChI Key
MGSRCZKZVOBKFT-UHFFFAOYSA-N
InChI
InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h4-7,11H,1-3H3
IUPAC Name
5-methyl-2-(propan-2-yl)phenol
SMILES
CC(C)C1=CC=C(C)C=C1O

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Thymol is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Thymol.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Thymol is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Thymol is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Barnidipine.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Thymol is combined with Bencyclane.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Benidipine.Approved, Investigational
BepridilThe risk or severity of adverse effects can be increased when Thymol is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Thymol.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Thymol.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Thymol is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Thymol is combined with Caroverine.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Thymol is combined with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Thymol.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Clevidipine.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Thymol.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Thymol is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Thymol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Thymol is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Thymol.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Thymol.Approved
DotarizineThe risk or severity of adverse effects can be increased when Thymol is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Efonidipine.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Thymol is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Thymol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Thymol is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Thymol is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Thymol is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Thymol can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Thymol is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Thymol is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Thymol is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Thymol is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Lercanidipine.Approved, Investigational
LidoflazineThe risk or severity of adverse effects can be increased when Thymol is combined with Lidoflazine.Experimental
LosartanThe metabolism of Losartan can be decreased when combined with Thymol.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Thymol is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Thymol is combined with Manidipine.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Thymol is combined with Mibefradil.Investigational, Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Thymol is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Thymol is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Thymol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Thymol is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine.Approved, Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Thymol is combined with Otilonium.Experimental, Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Thymol is combined with Perhexiline.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Thymol.Approved, Vet Approved
PinaveriumThe risk or severity of adverse effects can be increased when Thymol is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Thymol is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Thymol is combined with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Thymol.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Thymol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Thymol.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Thymol.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Thymol.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Thymol.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Thymol.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Thymol is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Thymol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Thymol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Thymol.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Thymol.Approved, Investigational
TerodilineThe risk or severity of adverse effects can be increased when Thymol is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Thymol is combined with Tetrahydropalmatine.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Thymol is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Thymol is combined with Tranilast.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Thymol is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Thymol is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Thymol is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Thymol is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Thymol.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB01878
KEGG Drug
D01039
KEGG Compound
C09908
PubChem Compound
6989
PubChem Substance
46504674
ChemSpider
21105998
BindingDB
50240432
ChEBI
27607
ChEMBL
CHEMBL29411
IUPHAR
2499
Guide to Pharmacology
GtP Drug Page
HET
IPB
PDB Entries
1e06

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentAggressive Periodontitis1
Not AvailableRecruitingTreatmentPeriodontitis / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
OilTopical.7 g/50g
OilTopical1.5 g/50g
LiquidDental
RinseOral
MouthwashBuccal
LiquidTopical.5 mL/L
SprayTopical.06 mL/120mL
LotionTopical
SprayTopical
PowderTopical
OintmentTopical
OilTopical.5 g/50g
SoapTopical.0004 1/kg
SoapTopical.0004 kg/kg
SprayTopical.0005 kg/kg
ClothTopical.0005 kg/kg
MouthwashBuccal; Oral
LiquidOral
OilTopical1.7 g/50g
GelTopical
MouthwashDental; Oral
MouthwashOral
JellyNasal
LiquidTopical
SoapTopical.0024 kg/kg
LozengeOral
PlasterTopical
PatchCutaneous; Topical; Transdermal
MouthwashDental
LiquidRespiratory (inhalation)
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)51.5 °CPhysProp
boiling point (°C)232.5 °CPhysProp
water solubility900 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.30HANSCH,C ET AL. (1995)
pKa10.6 (at 20 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.643 mg/mLALOGPS
logP3.16ALOGPS
logP3.43ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)10.59ChemAxon
pKa (Strongest Basic)-5.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity47.27 m3·mol-1ChemAxon
Polarizability17.84 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9381
Caco-2 permeable+0.9153
P-glycoprotein substrateNon-substrate0.722
P-glycoprotein inhibitor INon-inhibitor0.9343
P-glycoprotein inhibitor IINon-inhibitor0.9883
Renal organic cation transporterNon-inhibitor0.9036
CYP450 2C9 substrateNon-substrate0.7352
CYP450 2D6 substrateSubstrate0.7838
CYP450 3A4 substrateNon-substrate0.5667
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9368
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7429
Ames testNon AMES toxic0.9282
CarcinogenicityNon-carcinogens0.7195
BiodegradationNot ready biodegradable0.7808
Rat acute toxicity2.2996 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8987
hERG inhibition (predictor II)Non-inhibitor0.9087
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-000i-0900000000-333dc57384e65e3b4cfa
GC-MS Spectrum - EI-BGC-MSsplash10-000i-1900000000-3679938a5ea114a30e48
GC-MS Spectrum - EI-BGC-MSsplash10-000i-3900000000-8ce5865e48dad7250d5e
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-0109030000-5562c203cb318f30321b
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0a4i-2492200000-85342d698be72263a95f
Mass Spectrum (Electron Ionization)MSsplash10-000i-4900000000-73edaa628c1f5f2e1bd9
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-01p9-9700000000-e1a28495617d7b014e5c
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-014i-9300000000-baeee6cdcafaadeebdec
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-015c-9100000000-e1efa41eaf818832448a
MS/MS Spectrum - EI-B (SHIMADZU LKB-9000B) , PositiveLC-MS/MSsplash10-000i-0900000000-333dc57384e65e3b4cfa
MS/MS Spectrum - EI-B (HITACHI RMU-6L) , PositiveLC-MS/MSsplash10-000i-1900000000-3679938a5ea114a30e48
MS/MS Spectrum - EI-B (HITACHI M-80B) , PositiveLC-MS/MSsplash10-000i-3900000000-f72f603d97f0f7081b8d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Aromatic monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Phenylpropanes / Cumenes / Meta cresols / Toluenes / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Cumene / Phenylpropane / M-cresol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Toluene
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, monoterpenoid (CHEBI:27607) / Menthane monoterpenoids, Cyclic monoterpenes (C09908) / Menthane monoterpenoids (LMPR0102090029)

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:15